Literature DB >> 10996024

Intratracheal administration of anaphylatoxin C5a potentiates antigen-induced pulmonary reactions through the prolonged production of cysteinyl-leukotrienes.

M Kodani1, N Sakata, Y Takano, H Kamiya, T Katsuragi, T E Hugli, M Abe.   

Abstract

The effects of intratracheal administration of anaphylatoxin C5a on airway inflammation have been studied using two sources of material, zymosan activated serum (ZAS) and purified rat C5a des Arg, in order to determine the influence of complement activation on allergic airway disorders.The intratracheal administration of ovalbumin (OA) to OA-sensitized rats generated two phases of airway response, an immediate airway response (IAR) occurring within 15 min and a late airway response (LAR) beginning 4-6 h after the allergen challenge. The simultaneous administration of ZAS and OA into the trachea generated a sustained elevation of airway resistance (Raw) following IAR, while that of OA or ZAS alone resulted in Raw returning nearly to the baseline just after the IAR. The elevation of Raw after the combined challenge of OA and ZAS was significantly inhibited by pretreatment with a CysLT(1) receptor antagonist, pranlukast 30 mg/kg, but after that OA or ZAS alone was not significantly inhibited by pranlukast. The intratracheal administration of purified C5a produced an airway response that was similar to, but higher than, that evoked by ZAS. Namely, the challenge with OA plus C5a resulted in a higher IAR than OA plus ZAS, and also caused an early animal death up to 6 h, which was prevented by a combined pretreatment with pranlukast and the H(1) receptor antagonist, diphenhydramine.A histological examination at 6 h after the OA challenge identified an infiltration of inflammatory cells into the bronchial submucosal tissue, with a predominance of neutrophils and fewer eosinophils. On the other hand, a histological examination after the OA and ZAS challenge showed more severe infiltration of granulocytes into the bronchial submucosal tissue than that with OA or ZAS alone. The challenge with OA plus C5a was associated with severe perivascular leakage in the lungs and the combined pretreatment with both the antagonists led to a marked reduction in perivascular leakage. The quantitation of N-acetyl-leukotriene E(4) (N-Ac-LTE(4)), a major metabolite of cysteinyl-leukotrienes (cysLTs), in the bile indicated a significantly greater and longer excretion of cysLTs, from 1 to 6 h after the combined challenge, than that after either OA or ZAS alone. This suggested a prolonged generation of cysLTs in the lung by the combined challenge.In conclusion, our findings suggest that anaphylatoxin C5a may mediate the airway inflammatory response induced by a specific antigen challenge partly through a prolonged production of cysLTs and the release of histamine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996024     DOI: 10.1016/s0162-3109(00)00240-x

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  4 in total

Review 1.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain.

Authors:  E Ting; A T G Guerrero; T M Cunha; W A Verri; S M Taylor; T M Woodruff; F Q Cunha; S H Ferreira
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

3.  Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption.

Authors:  Lydia A Hanna; Emad B Basalious; Omaima N ELGazayerly
Journal:  Drug Deliv       Date:  2016-11       Impact factor: 6.419

4.  C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera.

Authors:  Felipe Silva de França; Isadora Maria Villas-Boas; Bruno Cogliati; Trent M Woodruff; Edimara da Silva Reis; John D Lambris; Denise V Tambourgi
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.